Arginine pyroglutamate

Other Names

(2S)-2-amino-5-(diaminomethylideneamino)pentanoic acid;(2S)-5-oxopyrrolidine-2-carboxylic acid5-oxo-L-proline L-arginine salt5-oxo-L-proline, compound with L-arginine (1:1)AdiuvantArgidoneArginina pidolatoArgininapidolatoArginine L-pyroglutamateArginine PCAArginine PCA [INCI]Arginine pidolateArgininepidolateG-278L-ARG L-PCAL-Arg-L-PyrL-Arginine compd. with 5-oxo-L-proline (1:1)L-Arginine L-2-pyrrolidone-5-carboxylateL-Arginine L-pyroglutamateL-Arginine pyroglutamateL-Arginine pyroglutamic acidL-Proline, 5-oxo-, compd. with L-arginine (1:1)PirglutargineProline, 5-oxo-, L-, compd. with L-arginine (1:1)Pyrglutargine

Synopsis

Arginine Pyroglutamate

1. Identity and Chemical Characterization

Names and Synonyms

L-Arginine L-pyroglutamate, also known as pirglutargine and arginine pidolate, is the L-arginine salt of pyroglutamic acid. Additional synonyms documented in chemical databases include arginine PCA, pyrglutargine, and the systematic IUPAC designation (2S)-2-amino-5-(diaminomethylideneamino)pentanoic acid;(2S)-5-oxopyrrolidine-2-carboxylic acid, with a molecular formula of C₁₁H₂₁N₅O₅ and a molecular weight of 303.32 g/mol. Its CAS registry number is 56265-06-6, and its FDA UNII code is 808T94CEU6.

Physical Properties

L-Arginine L-pyroglutamate is the L-arginine salt of pyroglutamic acid, existing as a crystalline solid powder with a sour taste. It is soluble in cold water.

Structural Nature

Arginine pyroglutamate is a salt compound formed by the ionic association of two distinct amino acid-related molecules. Pyroglutamic acid (also known as PCA, 5-oxoproline, or pidolic acid) is a ubiquitous but understudied natural amino acid derivative in which the free amino group of glutamic acid or glutamine cyclizes to form a lactam. L-Arginine (Arg) serves not only as a building block of protein but also as an essential substrate for the synthesis of nitric oxide (NO), creatine, polyamines, homoarginine, and agmatine in mammals, including humans. In the salt form, the guanidinium group of arginine forms an ionic pair with the carboxylate of pyroglutamic acid. Arginine pyroglutamate is therefore a delivery form of arginine.

2. Natural Sources and Occurrence

Pyroglutamic Acid (the Pyroglutamate Component)

Pyroglutamate (also called 2-oxo-pyrrolidone carboxylic acid, or PCA) is an amino acid naturally occurring in vegetables, fruits, dairy products, and meat, and is also normally present in large amounts in the human brain, cerebrospinal fluid, and blood. It is a metabolite in the glutathione cycle that is converted to glutamate by 5-oxoprolinase.

Pyroglutamic acid is present in many cheese varieties and particularly in high amounts (0.5 g/100 g of cheese) in extensively ripened Italian cheeses such as Grana Padano and Parmigiano Reggiano, produced with thermophilic lactic acid bacteria as starters. The mechanism of pyroglutamic acid formation in cheese appears to be mostly enzymatic, as demonstrated by the exclusive presence of the L-pyroglutamic acid enantiomer. Thermophilic lactobacilli are implicated in pyroglutamic acid production, and pyroglutamic acid concentration is linearly correlated (R² = 0.94) with the age of Grana Padano cheese.

L-Pyroglutamic acid (also known as PCA, 5-oxoproline, pidolic acid) is a five-membered lactam of glutamic acid. It occurs naturally in fruits, some plant foods, dairy, and fermented products such as soy sauce, and is a metabolite in the glutathione cycle, converted to glutamate by 5-oxoprolinase.

Pyroglutamate is found in many proteins including bacteriorhodopsin. N-terminal glutamic acid and glutamine residues can spontaneously cyclize to become pyroglutamate, or be enzymatically converted by glutaminyl cyclases.

L-Arginine

L-Arginine, classified as a semi-essential amino acid, plays a central role in numerous physiological processes, most notably as a precursor for nitric oxide (NO) synthesis. It is obtained from dietary protein sources and is synthesized endogenously via the urea cycle.

The Combined Salt Form

The combined salt, arginine pyroglutamate, does not occur in significant concentrations as a discrete entity in nature. It is prepared synthetically for commercial and research purposes. During manufacturing, the L-arginine L-pyroglutamate compound is dried to remove residual solvents or moisture and is isolated in its final form, such as a powder.

3. Common Forms and Preparations

Arginine pyroglutamate is most commonly available in capsules or powder, sometimes combined with other amino acids like lysine for synergistic effects. The final L-arginine L-pyroglutamate product is typically packaged in appropriate containers, such as capsules, tablets, or bulk powder, depending on its intended use. In earlier Italian pharmaceutical and clinical research, it was also studied in oral solution and injectible forms.

Supplements of arginine are commonly ingested as the Cl⁻ salt or as the salt of other anions such as α-ketoglutarate, aspartate, pyroglutamate, or malate. Among these salt forms, the pyroglutamate combination has attracted particular interest due to the proposed complementary biological activities of its two constituent moieties.

4. Historical and Traditional Use

Pharmaceutical Origins in Italy

Arginine pyroglutamate has no documented history of traditional herbal or ethnobotanical use predating the modern pharmaceutical era. Its history is pharmacological rather than botanical, originating in Italian pharmaceutical research during the 1970s. The compound was formally characterized in published literature in 1977: a key early paper titled "Chemistry and pharmacology of arginine pyroglutamate: Analysis of its effects on the CNS" was authored by Provenzano PM, Brucato A, Gianguzza S, Coppola A, Orzalesi G, Selleri R, Innocenti F, and Volpato I, published in Arzneimittelforschung in 1977 (PMID: 578745). A companion Italian-language paper also published in 1977 described the "chemico-pharmaceutical and pharmacodynamic characteristics of pyrglutargine" (Bollettino Chimico Farmaceutico, PMID: 610732).

The compound was developed and studied primarily within the Italian pharmaceutical and nutritional science tradition during the late 1970s through the 1990s, with interest focusing on two principal areas: central nervous system (CNS) activity attributed to the pyroglutamate moiety, and growth hormone secretagogue properties of the arginine component.

Early Research Context

Pyroglutamic acid itself had a longer research history, with investigations into its cognitive properties predating the development of the arginine salt. In neurology, the brain-boosting effects of PCA were reportedly discovered in 1984. Research in the 1980s and early 1990s then explored the pyroglutamic acid moiety for memory and cognitive applications, and the arginine salt was studied as a means of delivering both compounds simultaneously.

5. Key Constituents and Mechanisms of Action

The Arginine Moiety: Nitric Oxide Synthesis

The biochemistry and physiology of L-arginine must be understood in light of the discovery that the amino acid is the only substrate of all isoforms of nitric oxide synthase (NOS). Generation of nitric oxide — a versatile molecule in signaling processes and nonspecific immune defense — is intertwined with synthesis, catabolism, and transport of arginine, which thus ultimately participates in the regulation of a fine-tuned balance between normal and pathophysiological consequences of NO production.

Nitric oxide (NO) serves as a critical mediator of vascular function, contributing to vasodilation, the regulation of blood flow, and the prevention of thrombosis. As a primary precursor of NO, L-arginine is essential for maintaining endothelial integrity, modulating mitochondrial function, and reducing oxidative damage.

L-Arginine is the substrate for vascular nitric oxide formation. Under normal physiological conditions, intracellular L-arginine levels far exceed the K_m of NO synthase for L-arginine. However, endogenous NO formation is dependent on extracellular L-arginine concentrations, giving rise to the concept of the "L-arginine paradox."

L-Arginine serves not only as a building block of protein but also as an essential substrate for the synthesis of NO, creatine, polyamines, homoarginine, and agmatine. NO, a major vasodilator, increases blood flow to tissues. Arginine and its metabolites play important roles in metabolism and physiology; arginine is required to maintain the urea cycle in an active state to detoxify ammonia.

The Arginine Moiety: Growth Hormone Stimulation

Arginine can modulate growth hormone (GH) release by suppressing its endogenous inhibitory regulator, somatostatin. Arginine also induces the release of GH-releasing hormone (GHRH).

The Pyroglutamate Moiety: CNS and Cognitive Mechanisms

Pyroglutamic acid is a cyclic derivative of glutamic acid having procholinergic properties and promnesic (memory-enhancing) effects in both animals and humans. After oral administration, pyroglutamate passes into the brain through the blood-brain barrier and stimulates cognitive functions.

Pyroglutamic acid is an understudied natural amino acid derivative in which the free amino group of glutamic acid or glutamine cyclizes to form a lactam. L-Pyroglutamic acid (pGlu), a cyclic derivative of L-glutamic acid, has been described as having multifaceted roles in neuroscience and has historically been viewed as a metabolic intermediate in the γ-glutamyl cycle.

Regarding cholinergic interactions: pyroglutamyl peptides are formed from intramolecular cyclization of glutamine or glutamic acid residues at the N-terminal position of peptides; this process can occur endogenously or during processing of foods containing the peptides. Some health-promoting properties have been reported for pyroglutamyl peptides, including hepatoprotective, antidepressant, and anti-inflammatory activities. However, the role of the pyroglutamate residue in peptide bioactivity is not completely established, although the hydrophobic γ-lactam ring is thought to enhance peptide stability against degradation by gastrointestinal proteases.

Pyroglutamic acid is also a natural humectant in skin and part of its natural moisturizing factor (NMF).

6. Scientific Evidence by Area of Use

6.1 Growth Hormone Secretion

The Isidori et al. (1981) Study

The most frequently cited human clinical study on arginine pyroglutamate is a 1981 paper by Isidori, Lo Monaco, and Cappa. Isidori, Lo Monaco, and Cappa, publishing in Current Medical Research and Opinion in 1981, studied 15 healthy male volunteers and reported that oral administration of 1,200 mg L-lysine combined with 1,200 mg L-arginine pyroglutamate provoked a release of pituitary somatotropin and insulin, while neither amino acid alone at equivalent doses produced meaningful GH stimulation.

A study was carried out in 15 male volunteers to evaluate qualitatively the secretion of growth factors following stimulation by oral amino acids. The results showed that oral administration of a combination of two amino acids (1,200 mg L-lysine plus 1,200 mg L-arginine) provoked a release of pituitary somatotropin and insulin. This phenomenon was reproducible and the growth hormone secreted in response to this stimulation had biological activity, as demonstrated by a radioreceptor assay and somatomedin induction.

1,200 mg of lysine (as hydrochloride) paired with 1,200 mg arginine (as 2-pyrrolidone-5-carboxylate) was able to increase secretion of insulin and somatotropin, which promoted growth hormone secretion; the peak value was at 90 minutes after ingestion and reached 7.94-fold baseline levels. There was no placebo for comparison. It was reported to be synergistic, as either agent alone at the same dose failed to promote growth hormone secretion, and measurements lasted 120 minutes.

In the same study of 15 healthy male subjects, separate consumption of arginine pyroglutamate or lysine as single nutrients did not significantly increase growth hormone compared to baseline.

Evidence Strength and Limitations

The evidence for growth hormone secretion from this specific combination must be characterized as preliminary and limited. This small, acute 1981 paper is the most frequently invoked study in this context. Key methodological limitations include a small sample size (n=15), the lack of a placebo control group, a single-dose, acute-administration design, restriction to young healthy males aged 15–20, and the absence of blinding. These limitations prevent firm conclusions about clinical efficacy.

Subsequent studies with higher doses of arginine combined with lysine have not replicated the acute findings under chronic administration conditions. A later study using 3 g of L-arginine paired with 3 g L-lysine twice daily (12 g total) for 12 days in both young and elderly men failed to find appreciable increases in 24-hour AUC measurements of growth hormone, and this failure has been replicated in a study using 2 g each of L-arginine, L-ornithine, and L-lysine in weight-trained men.

Arginine and GH: Broader Systematic Evidence

A 2022 systematic review and meta-analysis published in Oxidative Medicine and Cellular Longevity (PMC9712012) examined GH responses to L-arginine more broadly. Meta-analyses showed significant effects of arginine alone on GH release (MD = 10.07, 95% CI: 7.87, 12.28). Moreover, the response of GH was greater with arginine in combination with GHRH (MD = 24.96, 95% CI: 17.51, 32.42). There was no significant difference between patients and healthy individuals, or between oral and injectable use of arginine. However, this review addressed L-arginine broadly, not specifically arginine pyroglutamate.

6.2 Cognitive Function and Memory

Human Clinical Evidence for Pyroglutamic Acid

Because the pyroglutamate component is considered the primary driver of cognitive effects, the most relevant human evidence concerns pyroglutamic acid (PCA) itself, published largely in Italian pharmacological literature. Pyroglutamic acid (PCA) was compared with placebo in a randomized, double-blind trial for assessing its efficacy in treating memory deficits in 40 aged subjects. Twenty subjects were treated with PCA and 20 with placebo over a period of 60 days. Memory functions were evaluated at baseline and after 60 days by means of a battery of six memory tasks. The results suggest that PCA is effective in improving some verbal memory functions in subjects affected by age-related memory decline. (Grioli et al., Fundamental & Clinical Pharmacology, 1990; PMID: 2190900.)

Additional evidence cited in the literature refers to pyroglutamate's effects in patients with alcohol-induced memory deficits and multi-infarct dementia. In patients with multi-infarct dementia, the administration of pyroglutamate reportedly brought about a significant increase of attention and an improvement on psychological tests investigating short-term retrieval, long-term retrieval, and long-term storage of memory. A statistically significant improvement was observed also in the consolidation of memory.

Animal Evidence

The effects of the arginine salt of pyroglutamic acid on learning and memory capacities of old rats were studied in a subchronic treatment schedule (intraperitoneal injection of 0.1 and 1 g/kg/day for 15 days). The acquisition and extinction of active avoidance behavior were studied in a pole-jumping test. PCA facilitated the rate of acquisition of pole-jumping response and inhibited its extinction; the dose of 1 g/kg was more potent than 0.1 g/kg. In the passive avoidance task, treatment with PCA was also followed by an improvement of avoidance retention. (PubMed PMID: 3402813.) These results indicate PCA is behaviorally active in aged rats, but extrapolation to humans requires caution.

Related Pyroglutamate Conjugates

A separate compound, dimethylaminoethanol pyroglutamate (DMAE p-Glu), shares the pyroglutamic acid moiety and was studied in both preclinical and clinical settings. DMAE p-Glu results from the reaction between dimethylaminoethanol (an indirect precursor of acetylcholine) and pyroglutamic acid (a cyclic derivative of glutamic acid having procholinergic properties and promnesic effects in both animals and humans). The study undertook preclinical and clinical evaluations to test a potential therapeutic utility for DMAE p-Glu in cognitive impairments related to central cholinergic deficit. These results indicate that DMAE p-Glu reduces the deleterious effect of scopolamine on long-term memory in healthy volunteers and suggest that DMAE p-Glu might be effective in reducing memory deficits in patients with cognitive impairment. While informative about the pyroglutamate moiety's cholinergic properties, this evidence does not directly pertain to arginine pyroglutamate specifically.

Evidence Strength

The evidence base for cognitive effects is preliminary and of limited methodological quality. The clinical studies on PCA for age-related memory decline are small (n=40 at most), old, and have not been replicated in well-powered, modern randomized controlled trials. Animal data support plausibility but cannot be directly extrapolated to human cognition. No large-scale, rigorously controlled clinical trials of arginine pyroglutamate as the specific combined compound for cognitive outcomes have been identified in the peer-reviewed literature.

6.3 Cardiovascular and Vascular Function

The arginine component of this compound has been extensively studied in cardiovascular contexts via its role in nitric oxide synthesis. Supplementation of L-arginine for short periods of time has been found useful in treating cardiovascular diseases including hypertension, atherosclerosis, coronary heart disease, heart failure, peripheral vascular disease, and type 2 diabetes, but efficacy requires very high daily dosages ranging from 6 to 24 g per day.

Evidence is mixed overall. In clinical trials, short- to medium-term administration of L-arginine improved the symptoms of cardiovascular disease. In other trials, however, L-arginine was not beneficial, and in one recent long-term study, higher mortality of subjects receiving L-arginine than those receiving placebo was reported. The endogenous inhibitor of nitric oxide synthase, asymmetric dimethylarginine (ADMA), may determine a subject's response to L-arginine. L-Arginine appears to exert no effect in subjects with low ADMA levels, whereas in subjects with high ADMA levels L-arginine restores the L-arginine/ADMA ratio to normal and normalizes endothelial function.

No clinical trials specifically assessing cardiovascular outcomes of arginine pyroglutamate (as the combined salt) have been identified in the peer-reviewed literature. The cardiovascular evidence derives entirely from studies of L-arginine in various other salt or free-base forms.

6.4 Immune Function and Wound Healing

L-Arginine is a substrate for multiple immunologically relevant processes. Generation of nitric oxide, a versatile molecule in signaling processes and nonspecific immune defense, is intertwined with the synthesis, catabolism, and transport of arginine. Clinical evidence for immune modulation by L-arginine has been observed primarily in studies using immunonutrition formulas in surgical and critically ill patients, typically involving multi-ingredient preparations rather than arginine pyroglutamate as a standalone compound.

6.5 Skin Hydration

Pyroglutamic acid is a natural humectant in skin and part of its natural moisturizing factor (NMF). Sodium pyroglutamate (the sodium salt of pyroglutamic acid) is widely used as a humectant in topical cosmetic formulations. This application is distinct from the oral supplemental use of arginine pyroglutamate and involves the pyroglutamate component in topical, not systemic, application.

7. Body Systems Associated with Arginine Pyroglutamate

Central Nervous System: Cognitive effects, memory, cholinergic activity — primarily through the pyroglutamate moiety, which crosses the blood-brain barrier.
Endocrine System: Pituitary growth hormone secretion — through the arginine-mediated suppression of somatostatin and induction of GHRH, with synergistic effects reported in combination with L-lysine.
Cardiovascular System: Vasodilation, blood pressure regulation, endothelial function — mediated by L-arginine's role as the precursor to nitric oxide.
Immune System: NO-mediated immune defense, lymphocyte proliferation — attributable to the arginine component.
Integumentary System (Skin): The pyroglutamate moiety contributes to skin natural moisturizing factor when present in topical preparations.
Metabolic / Urea Cycle: Arginine is required to maintain the urea cycle in an active state to detoxify ammonia.

8. Dosage: Forms and Doses Reported in Studies

Dosage data are sparse and derived primarily from a small number of studies. The following represent doses as stated in cited sources only:

Growth hormone secretagogue (human, oral): 1,200 mg of L-arginine pyroglutamate combined with 1,200 mg of L-lysine hydrochloride (Isidori et al., 1981, in 15 male volunteers).
Arginine + lysine chronic administration (human, oral): 3 g of L-arginine paired with 3 g L-lysine twice daily (12 g total per day) for 12 days, studied in both young and elderly men — this study did not find appreciable 24-hour GH increases.
Pyroglutamic acid for memory (human, oral): PCA was compared with placebo in 40 aged subjects; 20 received PCA for 60 days. (Specific dose not reported in the abstract retrieved; the intervention was described by the authors as effective for verbal memory.)
Animal study (arginine salt of PCA): Intraperitoneal injection of 0.1 and 1 g/kg/day for 15 days in rats.
Cardiovascular use of L-arginine (various forms): Efficacy for cardiovascular diseases has been studied at very high daily dosages ranging from 6 to 24 g per day. These doses apply to L-arginine broadly, not specifically to the pyroglutamate salt form.

There is no established Recommended Dietary Allowance (RDA) or official therapeutic dose for arginine pyroglutamate as a combined compound. There is no official Recommended Dietary Allowance for pyroglutamic acid.

9. Safety Considerations and Interactions

Gastrointestinal Effects of Arginine

L-Arginine (but not lysine, ornithine, or D-arginine) induces water and electrolyte secretion mediated by NO, which acts as an absorbagogue at low levels and as a secretagogue at high levels. The action of many laxatives is NO-mediated, and there are reports of diarrhea following oral administration of arginine or ornithine. The preponderance of clinical reporting identifies nausea, vomiting, and diarrhea as the typical side effects of oral arginine, with symptoms more likely at larger single doses and higher daily regimens; single doses of 3–6 g rarely provoke problems, whereas doses above approximately 9 g have been associated with GI symptoms and laxative-type effects in athletes and healthy adults.

Cardiovascular Risks at High Doses and in Specific Populations

The effects of L-arginine are dose-dependent, with low doses exerting a protective effect by generating NO, while high doses may lead to tissue damage by increasing oxidative stress and inflammatory responses. A number of studies, particularly long-term studies, have demonstrated no beneficial effect of L-arginine supplementation for patient populations with underlying cardiovascular abnormalities, and some studies have found that L-arginine supplementation can cause significant adverse events. One long-term clinical trial reported higher mortality in the L-arginine group compared to placebo in post-myocardial infarction patients — a finding that warrants caution.

The 5-Oxoprolinuria / Pyroglutamic Acidosis Issue

A pharmacologically important safety consideration concerns pyroglutamic acid's role in the γ-glutamyl cycle and the phenomenon of 5-oxoprolinuria (also called pyroglutamic aciduria or pyroglutamic acidosis). This is distinct from supplementation with arginine pyroglutamate but reflects an important metabolic interaction involving the pyroglutamate moiety.

A rare cause of high anion gap acidosis is 5-oxoproline (pyroglutamic acid), an organic acid intermediate of the γ-glutamyl cycle. Acetaminophen and several other drugs have been implicated in the development of transient 5-oxoprolinemia in adults. An acquired deficiency of glutathione secondary to paracetamol (acetaminophen) ingestion results in loss of feedback inhibition and enhances the production of 5-oxoproline, leading to a metabolic acidosis and 5-oxoprolinuria. Pyroglutamic acidosis can occur due to glutathione depletion in patients who receive flucloxacillin or vigabatrin together with paracetamol.

Inherited abnormalities of 5-oxoprolinase, which are autosomal recessive traits, cause the accumulation of 5-oxoproline and generate 5-oxoprolinemia and 5-oxoprolinuria; clinical manifestations include neonatal hypoglycemia, microcytic anemia, and intellectual deficits. Additionally, genetic glutathione synthetase defects also reduce glutathione levels and generate overproduction of 5-oxoproline.

While these drug-induced and hereditary conditions involve endogenous pyroglutamic acid accumulation rather than exogenous supplementation, individuals with genetic disorders of the γ-glutamyl cycle, or those concomitantly using acetaminophen, flucloxacillin, or vigabatrin, may face heightened risks when consuming additional pyroglutamic acid or its salts.

Arginine Hydrochloride-Specific Acidosis Risk

Arginine hydrochloride contains 4.8 mequivalents Cl⁻/g and may provoke a hyperchloremic acidosis if taken acutely in excess. The pyroglutamate salt form of arginine avoids this specific chloride-related acid load, which has been considered an advantage of organic arginine salts.

Long-Term Safety

Long-term safety of arginine is less certain: mechanistic and some clinical reviews raise concerns about reduced efficacy and potential maladaptive effects with prolonged L-arginine exposure, while high doses more often produce adverse GI outcomes. Specific long-term safety data for arginine pyroglutamate as the combined salt are absent from the published peer-reviewed literature.

Asymmetric Dimethylarginine (ADMA) Interaction

The endogenous inhibitor of nitric oxide synthase, ADMA, may determine a subject's response to L-arginine. L-Arginine appears to exert no effect in subjects with low ADMA levels, whereas in subjects with high ADMA levels, L-arginine restores the L-arginine/ADMA ratio to normal and normalizes endothelial function. This suggests that baseline ADMA status is a relevant variable in predicting individual response to supplemental arginine.

10. State of the Evidence: Overall Assessment

The scientific evidence for arginine pyroglutamate as a combined compound is sparse, dated, and methodologically limited. The most-cited human clinical study (Isidori et al., 1981) involved only 15 subjects, lacked a placebo control, and assessed only acute, single-dose effects. The cognitive evidence for the pyroglutamic acid component, while suggestive in small randomized trials and animal models, has not been reproduced in large, well-controlled modern trials. The cardiovascular and immune evidence base relates to L-arginine broadly across various salt forms and is itself mixed, with longer-term studies failing to confirm benefit and some raising safety concerns. No systematic review or meta-analysis specifically addressing arginine pyroglutamate as the combined compound has been identified in the peer-reviewed literature. Claims extending beyond what the individual moieties — L-arginine and pyroglutamic acid — have separately demonstrated in clinical trials are not currently supported by the published evidence base.

References

Health Conditions

Health conditions that Arginine pyroglutamate may help support.

No conditions available.

Body Systems

Body systems that Arginine pyroglutamate may help support.

No body systems available.